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Human cytomegalovirus (HCMV) infects more than 80% of the global population. While
mostly asymptomatic, HCMV infection can be serious among the immunocompromised,
and it is implicated in chronic disease pathophysiology in adulthood. Large-scale
minimally invasive HCMV screening could advance research and public health efforts
to monitor infection prevalence and prevent or mitigate downstream risks associated
with infection. We examine the utility of measuring HCMV immunoglobulin-G (IgG) levels
in saliva as an index of serum levels. Matched serum and saliva samples from healthy
adults (N = 98; 44% female; 51% white) were assayed for HCMV IgG, total salivary
protein, and salivary markers related to oral inflammation, blood, and tissue integrity.
We examine the serum-saliva association for HCMV IgG and assess the influence
of participant characteristics and factors specific to the oral compartment (e.g., oral
inflammation) on HCMV IgG levels and cross-specimen relations. We found a robust
serum-saliva association for HCMV IgG with serum antibody levels accounting for
>60% of the variance in salivary levels. This relation remained after adjusting for key
demographic and oral immune-related variables. Compared to the serum test, the
salivary HCMV IgG test had 51% sensitivity and 97% specificity. With improvements
in assay performance and sample optimization, HCMV antibody levels in oral fluids may
be a useful proxy for serum levels.
Keywords: cytomegalovirus, saliva, serum, immunoglobulin-G, antibody, cytokine
INTRODUCTION
Cytomegalovirus (human betaherpesvirus 5, HHV-5, or HCMV) infection is ubiquitous in the
human population, infecting individuals of all ages and approximately 83% of people worldwide
(1). HCMV is transmitted primarily through bodily fluids (e.g., saliva, urine, and breast milk),
and, even in healthy individuals, HCMV is not cleared by the immune system (2). HCMV
can infect and replicate in most cell types throughout the body, and, after primary infection,
HCMV establishes latency in early myeloid lineage cells (2, 3). Latent HCMV can become
reactivated during periods of immunosuppression and/or re-exposure (4, 5). While most HCMV
infections are asymptomatic, primary infection and viral reactivation can have serious negative
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health effects among the immunocompromised (e.g., HIV-
infected individuals, organ transplant recipients) (3). Congenital
infection, caused by maternal HCMV primary infection,
reinfection, or reactivation during gestation, can also cause
life-long health and developmental disorders including
neurodevelopmental and cognitive problems and serious
hearing loss (3, 6). In addition to the well-established health risks
of HCMV among these special populations, in adults, HCMV
has also been implicated in the pathophysiology of oral and
systemic chronic diseases such as periodontal disease, cancer,
cardiovascular disease, and neuropsychiatric disorders (7–12).
Higher serum concentrations of HCMV antibodies have also
been associated with indices of aging and immunosenescence,
atherosclerosis, and a higher risk of all-cause mortality (7,
13–15). As with other herpes family viruses, elevated stress, via
its association with immune suppression and decreased immune
surveillance, may play a role in the negative health consequences
of HCMV infection and the risk of chronic disease. HCMV
replication and antibody levels have been found to increase
during periods of stress and stress-related immunosuppression
(16–20).
The impact of HCMV infection on health and development
may be especially high among low-resource and racial/ethnic
minority communities. Geographic, socioeconomic (SES), and
racial/ethnic disparities in HCMV infection rates and prevalence
worldwide are well documented with low SES and racial/ethnic
minority groups disproportionately affected (21–23). The marked
sociodemographic disparities in HCMV infections parallel
disparities in the rates of exposure to adversity, and HCMV’s
stress-linked mechanism for viral shedding and reactivation,
raises the possibility that monitoring HCMV antibody levels
could benefit public health efforts to prevent and mitigate
downstream risks associated with infection (24). Serum HCMV
immunoglobulin-G (IgG) tests are currently used in clinical
settings (25). Significant associations between the reactivity
and neutralizing capacity of serum IgG and salivary IgG
(26, 27) suggest promising opportunities to measure HCMV
prevalence using salivary IgG tests. Saliva-based HCMV testing
platforms for immunoreactivity could help maximize the
impact of HCMV screening by facilitating minimally invasive,
community, field, and home-based testing for antibody levels
on a large-scale. Such advances could support public health
surveillance programs for HCMV and HCMV-related disorders
and diseases, as well as expand clinical assessments for
individuals at high risk of HCMV infection and/or infection
complications (e.g., the immunocompromised and pregnant
women).
The emerging field of salivary bioscience [see (28) for review],
however, has cautioned that, when relating concentrations
of analytes measured in oral fluids to systemic measures,
oral-specific processes, such as local inflammation and tissue
repair and reconstruction in the mouth, may confound
their associations and ultimately limit their clinical utility
(29, 30). Oral health and disease are therefore important
potential confounders of salivary biomeasure concentrations
that may compromise our ability to accurately monitor
HCMV antibody levels in saliva. The potential impact of
oral-specific confounds on salivary HCMV antibody screening
is heightened among low SES and racial/ethnic minority
communities where disparities in oral and physical health
overlap with increased HCMV prevalence and infection rates
(21, 22, 31, 32). Identifying sociodemographic and oral and
physical health factors associated with HCMV antibody levels,
and the influence of these factors on HCMV antibody serum-
saliva associations, is an important step in developing a
saliva-based HCMV testing protocol that could be widely and
reliability implemented.
In the current investigation, matched serum and saliva
samples from a study of healthy adults were examined to address
these gaps in our understanding of salivary HCMV antibody
levels. Specifically, we explore the distribution and demographic
and health correlates of HCMV IgG levels in serum and saliva and
examine the serum-saliva association for HCMV IgG levels. We
evaluate the extent to which oral-specific confounds (i.e., salivary
flow rate, and markers related to oral inflammation, tissue
integrity, and blood leakage) are associated with salivary HCMV
IgG levels and influence its serum-saliva relation. We further
investigate whether the level of blood and the concentration of
total IgG in saliva affect the nature and/or strength of the serum-
saliva association for HCMV IgG. Finally, to assess the clinical
relevance of salivary HCMV IgG levels, we examine the ability
of the salivary HCMV IgG test results to accurately differentiate
across HCMV serostatus subgroups.
We anticipate a significant positive serum-saliva association
for HCMV IgG levels, and positive associations between salivary
markers related to inflammation and tissue integrity and salivary
HCMV IgG levels. We expect the serum-saliva relation for
HCMV IgG is strengthened when these oral-specific confounds
are accounted for in the models, and that the serum-saliva
association for HCMV IgG increases with increasing salivary
total IgG and with increasing blood leakage into saliva. We
expect salivary HCMV IgG test results correspond with HCMV
serostatus determinations.
MATERIALS AND METHODS
Study Design, Sample, and Procedures
This study examines data collected from a cross-sectional study
of healthy adults conducted in 2013–2014. Some of the data
included in this study were examined in previous papers. The
study design, participants, and methods, briefly summarized
below, are the same as previously described [e.g., (30)].
A convenience sample was recruited via community postings.
Potential participants were screened over the telephone, and
those who were eligible were invited to participate in the study.
During a single laboratory visit, study participants (N = 100) were
asked to provide blood and whole saliva samples and complete a
set of demographic and health questionnaires. Eligibility criteria
excluded participants reporting chronic and/or acute health
conditions, medication use (except hormonal contraceptives),
open wounds or sores in their mouths, and recent oral surgery.
In preparation for the study visit, participants were instructed to
refrain from eating and drinking for at least 1 h prior to the visit.
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Study procedures were approved by the university’s Institutional
Review Board, and participants were compensated $50.
Biospecimen Collection and Preparation
Resting samples of serum and saliva were collected from all
participants. Whole blood was drawn by venipuncture into
2 mL lavender/EDTA tubes, and additional blood was drawn
for serum isolation using an SST Tiger serum separator tube
(BD #367988, Becton-Dickenson). Serum was mixed well by
inversion and allowed to clot at room temperature for 30 min
(and not longer than 1 h). After clot activation, serum tubes
were spun in a refrigerated centrifuge at 2000 rpm for 10 min.
Following centrifugation, serum was aliquoted into 2.0 mL
Sarstedt cryovial tubes and frozen at −80◦C until assay. Whole,
unstimulated saliva was collected via passive drool. Saliva was
mixed well by inversion, frozen to precipitate mucin, and then
thawed to room temperature and mixed again by inversion and
vortexing. Saliva was then centrifuged at 3500 rpm for 15 min,
and the supernatant was transferred into 15 mL conical tubes.
Following mixing by inversion and vortexing, saliva samples were
aliquoted into 2.0 mL Sarstedt cryovials and stored at −80◦C
until assay. All serum and saliva assays were performed at the
Johns Hopkins University Center for Interdisciplinary Salivary
Bioscience Research laboratory.
Measures
HCMV IgG
Salivary and serum HCMV IgG levels were assessed in duplicate
using a diagnostic enzyme-linked immunosorbent assay designed
for use in serum/plasma from IBL International (REF: RE57061).
Serum samples were diluted 1:101 using 10 mM phosphate
buffer pH 7.2 ± 0.2 and tested according to manufacturer’s
protocol without modification. Saliva samples were assayed
following the same protocol; however, to maximize IgG levels
in the saliva, samples were tested without dilution (test
volume = 100 µL). Salivary and serum HCMV IgG results
were reported quantitatively [U/mL; (U = NovaTec Units)] and
qualitatively using manufacturer-provided threshold values for
a positive/negative test result. The cut-off value for HCMV IgG
level was based on the assay’s “cut-off control” (absorbance value
of 0.15–1.300; 10 NovaTec Units). Higher absorbance values
indicated a positive test result, lower absorbance values indicated
a negative test result, and samples within a 20% range of the cut-
off control were considered equivocal. The intra-assay precision
for salivary HCMV IgG tests was 5%, and the detection limit,
determined for five sets of blank duplicates (substrate only),
was 0.01 U/mL. The intra-assay coefficient of variation (CV) for
serum tests was 5%.
Demographic and Health Characteristics
Demographic and health characteristics (Table 1) were examined
as potential correlates of serum and salivary HCMV IgG levels
and serostatus. Participants reported their age, sex, race, ethnicity,
height, and weight on study questionnaires. Height and weight
were used to calculate participant body mass index (BMI) (33).
Participants also reported their self-perceived, current, physical
health relative to other adults their age [Likert-type scale from
TABLE 1 | Participant characteristics.
n (%)
Age [mean years (SD)] 23.71 (4.56)
Female 41 (44.10)
Race
White 44 (51.16)
African American 18 (20.93)
Other 24 (27.91)
Ethnicity
Non-Hispanic 71 (88.75)
Hispanic 9 (11.25)
Body mass index category
Underweight 4 (4.35)
Normal/Healthy weight 58 (63.04)
Overweight 25 (27.17)
Obese 5 (5.43)
Current health
Excellent/Very good 68 (73.12)
Good 17 (18.28)
Fair/Poor 8 (8.60)
General sleep quality
Excellent/Very good 45 (48.39)
Good 36 (38.71)
Fair/Poor 12 (12.90)
Typical hours of sleep per night [mean hours (SD)] 6.95 (1.08)
Oral Health Composite [mean score (SD)] 3.62 (0.84)
All measures are based on self-reported data. Body mass index categories:
underweight ≤ 18.50, normal/healthy weight = 18.5–24.9, overweight = 25.0–
29.9, obese ≥ 30. Percentages are based on complete data per variable. Missing
data = 4% for the oral health composite (n = 94); 5% for age, sex, current health,
and general sleep quality (n’s = 93); 6% for body mass index and typical hours of
sleep per night (n’s = 92); 12% for race (n = 86); 18% for ethnicity (n = 80). Oral
health composite scores could range from 0 to 5, and higher scores represent
better self-reported oral health.
1 (excellent) to 5 (poor)]; their typical sleep quality [Likert-type
scale from 1 (excellent) to 5 (poor)]; and the number of hours
they typically sleep each night.
Oral-Specific Covariates and Confounders
The influence of factors related to the oral environment,
including markers associated with oral health, inflammation,
and salivary flow rate [see (30)], on salivary HCMV IgG levels
and cross-specimen relations was examined using self-report and
biologic indices.
Self-reported oral health was indexed by a series of five
questions assessing participants’ frequency of brushing and
flossing (per day and week, respectively), level of access to
dental/oral health care [Likert-type scale from 1 (poor) to 5
(excellent)], and the presence of blood in saliva after oral care
routines (yes/no) and of cuts/sores in the mouth (yes/no).
Responses to these questions were rescaled and averaged to create
a standardized self-reported oral health composite score [ranging
from 0 to 5 with higher scores representing better self-reported
oral health; see (29) for additional details].
Tissue remodeling in the oral compartment, a biologic
marker related to oral health, was assessed with salivary
matrix metalloproteinase-8 (MMP-8) concentrations (34).
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A commercially available development kit (DuoSet ELISA, R&D
Systems, Cat# DY908) was used to assay salivary MMP-8 at a
1:50 dilution following the manufactures’ protocol. The assay has
a range of sensitivity from 62.5 to 4000 pg/mL and the inter- and
intra-assay CVs were 5 and 4%, respectively.
Oral inflammation was indexed by salivary concentrations
of four proinflammatory cytokines [interleukin (IL)-1β,
IL-6, IL-8, and tumor necrosis factor-α (TNFα)]. Cytokine
concentrations were measured using a Meso Scale Discovery
(MSD; Gaithersburg, MD, United States) 96-well format
multiplex electrochemiluminescence immunoassay with a
standard diluent (MSD# R51BB) following the manufacturer’s
guidelines. The MSD Discovery Workbench Software (v. 3.0.17)
determined cytokine concentrations using curve fit models
(4-PL with a weighting function option of 1/y2). Lower limits
of detection were <0.20 pg/mL, and the inter- and intra-assay
CVs were less than 8 and 5%, respectively. Concentrations of
the four cytokines were examined separately, and an average
oral inflammation composite score was also created for each
participant using standardized cytokine concentrations [M
(SD) = 0.00 (0.75), range:−0.77– 3.34].
Blood in the oral compartment was indexed by concentrations
of salivary transferrin (35, 36). Transferrin was measured using
the Salimetrics enzyme immunoassay kit (State College, PA,
United States; Cat# 1–1302) which has a range of sensitivity from
0.08 to 6.6 mg/dL. The inter- and intra-assay CVs were 5 and
3%, respectively.
Salivary total IgG was assayed following a laboratory-
developed procedure using goat anti-human IgG [details
provided in (29)]. Samples were diluted at 1:1250, and the
calibration curve range ranged from 0.78 to 50 ng/mL.
The average inter- and intra-assay CVs were <15% and
<6%, respectively.
Salivary flow rate was indexed by concentrations of salivary
total protein. Total protein was assessed using a Thermo
Scientific assay kit (PierceTM BCA Cat# 23225). The assay was
performed following the manufacturers’ guidelines.
Statistical Approach
Analytic Sample, Model Diagnostics, and Sensitivity
Analyses
One participant with incorrect serum HCMV IgG data was
excluded from analysis, and two participants with missing serum
HCMV IgG data were excluded from analyses examining serum
IgG. Model fit and diagnostics were examined for all analyses.
For each model, influential cases were identified, and sensitivity
analyses assessed the robustness of the findings when cases with
Cook’s Distance >1 and/or standardized residuals >±3 were
excluded. All linear regression models were performed using
the full analytic sample, and sensitivity analyses were performed
that stratified the sample by HCMV serostatus to assess whether
the observed findings were driven by significant effects within
a specific seronegative/seropositive subgroup. Analyses were
conducted using Stata SE 15.1 (Stata Corp LLC, College Station,
TX, United States) and R version 3.6.1 (R Core Team, 2019).
Statistical significance was set at α = 0.05.
What Are the Distributions and Demographic and
Health Correlates of HCMV IgG Levels in Serum and
Saliva? Is Salivary HCMV IgG Level Correlated With
Serum HCMV IgG Level?
We examined the distribution, range, and mean and median
values of HCMV IgG in serum and saliva in our sample. We
assessed the extent to which the demographic and physical health
characteristics of our sample were associated with HCMV IgG
levels and serostatus using parametric and non-parametric tests
of association, as appropriate based on the distribution of the
data. Variables significantly related to HCMV IgG levels and/or
serostatus were included as potential covariates in subsequent
models assessing the serum-saliva association for HCMV IgG.
A non-parametric correlation (Kendall’s τ correlation) and a
bivariate linear regression, assuming a log-normal distribution
of salivary HCMV IgG (Figure 1), examined the unadjusted
cross-specimen association for HCMV IgG levels. Differences
in the serum-saliva association across serostatus groups were
examined using an interaction between serum HCMV IgG level
and serostatus in the linear regression model, and stratified
correlation analyses were conducted to quantify the serum-saliva
association within each serostatus group.
Are Salivary HCMV IgG Levels Associated With Oral
Immune-Related and Saliva-Specific Confounds?
We used Kendall’s τ correlations to assess salivary HCMV IgG
relations with the self-reported oral health composite score, and
biologic indices related to oral inflammation (salivary cytokines),
tissue integrity (salivary MMP-8), blood in saliva (salivary
transferrin), and flow rate (salivary total protein).
Does the Relation Between Salivary and Serum
HCMV IgG Levels Strengthen After Accounting for
Oral Immune-Related Markers and Salivary Flow
Rate? Does the Relation Between Salivary and Serum
HCMV IgG Levels Increase With Increasing Levels of
Blood and Total IgG in Saliva?
Multivariable linear regression models for salivary HCMV IgG
level (dependent variable; assuming a log-normal distribution)
examined the adjusted relations between salivary and serum
HCMV IgG levels controlling for all significant oral immune-
related and saliva-specific covariates. To assess whether the level
of blood or the concentration of total IgG in saliva moderated the
adjusted serum-saliva relation for HCMV IgG, we included, in
separate models, interaction terms between serum HCMV IgG
and salivary transferrin levels and between serum HCMV IgG
and salivary total IgG levels.
Do Salivary HCMV IgG Test Results Accurately
Differentiate HCMV Serostatus Subgroups?
We calculated the sensitivity, specificity, and positive and
negative predictive values of the HCMV IgG test in saliva
vs. serum using the cut-off values for HCMV antibody levels
included in the testing kit. Standard formulae, adjusted
to account for equivocal saliva test results, were used
for these indices (37). Sensitivity, or the proportion of
cases with a positive serum test result that were correctly
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FIGURE 1 | Distribution of human cytomegalovirus (HCMV) IgG levels measured in serum and saliva from healthy adults. (Data are coded to represent HCMV test
results within biospecimen type).
classified as positive using the saliva test, was calculated as:
ntrue positives/(ntrue positives + nfalse negatives + nequivocal saliva tests with
positive serum tests
).
Specificity, or the proportion of cases with a negative
serum test result that were correctly classified as negative
using the saliva test, was calculated as: ntrue negatives/
(ntrue negatives + nfalse positives + nequivocal saliva tests with
negative serum tests
). Positive
predictive value, or the proportion of cases with a positive saliva
test result that also tested positive in serum, was calculated as:
ntrue positives/(ntrue positives + nfalse positives), and negative predictive
value, or the proportion of cases with a negative saliva test
result that also tested negative in serum, was calculated as:
ntrue negatives/(ntrue negatives + nfalse negatives).
RESULTS
One participant, with especially high concentrations of all
salivary analytes except salivary HCMV IgG (in the top 20th
percentile for total IgG, transferrin, IL-1β, IL-6, IL-8, TNFα, and
MMP-8), altered the fit of each statistical model conducted and
the trends of the observed associations. This participant was
excluded from the analytic sample for all analyses (N = 98). All
linear regression results are presented on the log scale.
What Are the Distributions and
Demographic and Health Correlates of
HCMV IgG Levels in Serum and Saliva?
Is Salivary HCMV IgG Level Correlated
With Serum HCMV IgG Level?
The study sample was majority white and reported overall
good physical and oral health (Table 1). Except for race,
none of the demographic nor physical health characteristics
were significantly associated with HCMV IgG level in serum
nor saliva, and they did not vary by HCMV serostatus.
Racial homogeneity in the study sample only allowed for
statistical comparisons between white (n = 44) and African
American participants (n = 18). On average, African
American participants had higher HCMV IgG levels in
both serum [MAfrican American(SD) = 18.44 U/mL (17.12) vs.
Mwhite(SD) = 6.53 U/mL (12.28), z(59) = −2.58, p < 0.01]
and saliva [MAfrican American(SD) = 8.30 U/mL (7.59) vs.
Mwhite(SD) = 4.31 U/mL (5.74), z(60) = −2.82, p < 0.01]
compared to white participants. A greater proportion of African
American participants were seropositive for HCMV than white
participants [56% vs. 16%, respectively, χ2(1) = 10.09, p< 0.01].
Descriptive statistics for all biomeasures are shown in Table 2.
HCMV IgG levels were significantly positively correlated across
biospecimen [τ(94) = 0.51, p< 0.001; Figure 2]. While the serum-
saliva relation was numerically stronger among seropositive
[τ(33) = 0.29, p < 0.05] compared to seronegative participants
[τ(59) = 0.15, p = 0.08], the unadjusted association between
salivary and serum HCMV IgG levels was significant in linear
regression models [b = 0.05, t(94) = 12.05, p < 0.001;
η2 = 0.61], and serostatus did not significantly moderate
this association.
Are Salivary HCMV IgG Levels
Associated With Oral Immune-Related
and Saliva-Specific Confounds?
Salivary HCMV IgG level was significantly positively associated
with all biologic measures related to oral inflammation, tissue
integrity, and blood leakage into saliva (Table 3). Self-reported
oral health composite scores, however, were not significantly
associated with salivary HCMV IgG levels. Salivary total protein
was also not significantly related to salivary HCMV IgG level.
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TABLE 2 | Descriptive statistics of biomeasures from a sample of healthy adults.
Mean Median SD Minimum Maximum n
Serum HCMV IgG (U/mL)a 13.09 1.67 16.37 0.39 52.55 96
Salivary HCMV IgG (U/mL) 6.32 3.29 7.78 0.62 38.78 98
Salivary IL-1β (pg/mL) 264.74 209.50 257.26 9.10 1,591.18 98
Salivary IL-6 (pg/mL) 9.79 4.07 16.57 0.35 120.93 98
Salivary IL-8 (pg/mL) 947.70 680.51 743.02 109.11 3,374.14 98
Salivary TNFα (pg/mL) 5.21 2.49 12.04 0.16 110.67 98
Salivary MMP-8 (pg/mL) 76,510.08 56,987.81 57,138.03 5,380.34 200,000.00 92
Salivary Transferrin (mg/dL) 0.69 0.37 0.79 0.04 4.69 98
Salivary Total IgG (µg/mL) 15.40 9.85 16.07 0.40 92.60 98
Salivary Total Protein (mg/mL) 702.99 616.22 367.25 148.53 1,911.19 98
HCMV, human cytomegalovirus; U, NovaTec Units; IgG, immunoglobulin-G; IL, interleukin; TNFα, tumor necrosis factor-α; MMP-8, matrix metalloproteinase-8; SD,
standard deviation. MMP-8 determinations that exceeded the assay’s upper limit of sensitivity (n = 10), were replaced with the upper limit (200,000 pg/mL). Six MMP-8
determinations were unreliable (coefficients of variation >15%) and therefore excluded from analysis. aHCMV IgG levels are biofluid specific, and, given the differences in
assay protocols employed, levels in serum and saliva should not be directly compared.
FIGURE 2 | Human cytomegalovirus (HCMV) IgG levels were positively correlated across biospecimen type (N = 96 healthy adults). (Data are coded by HCMV
serostatus).
Does the Relation Between Salivary and
Serum HCMV IgG Levels Strengthen
After Accounting for Oral
Immune-Related Markers and Salivary
Flow Rate? Does the Relation Between
Salivary and Serum HCMV IgG Levels
Increase With Increasing Levels of Blood
and Total IgG in Saliva?
The positive relation between salivary and serum HCMV
IgG levels remained significant after adjusting for salivary
transferrin, MMP-8, and the oral inflammation composite score
[b = 0.05, t(85) = 15.41, p < 0.001; η2 = 0.74]. Neither
salivary transferrin nor total IgG moderated the serum-saliva
association for HCMV IgG.
Do Salivary HCMV IgG Test Results
Accurately Differentiate HCMV
Serostatus Subgroups?
Table 4 shows the serum and salivary HCMV IgG test results.
Using the serum test result as the indicator of infection status, the
saliva test showed a sensitivity of 51% and a specificity of 97%.
Every participant with a positive salivary HCMV IgG test also had
a positive serum test (100% positive predictive value), and 87% of
participants with a negative salivary HCMV IgG test also had a
negative serum test (87% negative predictive value).
Adjustment for Race, Stratification by
Serostatus, and Sensitivity Analyses
Race (white vs. African American) was tested as a covariate in
all regression models presented above (subsampled for white and
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TABLE 3 | Salivary human cytomegalovirus IgG levels were positively correlated
with all markers related to oral inflammation and tissue integrity (N = 98).
Kendall’s τ correlation coefficient
Salivary IL-1β 0.23***
Salivary IL-6 0.27***
Salivary IL-8 0.19**
Salivary TNFα 0.17*
Salivary MMP-8a 0.21**
Salivary Transferrin 0.28***
Oral Inflammation Composite Score 0.23**
IL, interleukin; TNFα, tumor necrosis factor-α; MMP-8, matrix metalloproteinase-8;
salivary oral inflammation composite score = standardized mean of salivary IL-1β,
IL-6, IL-8, and TNFα. aMMP-8 correlation test n = 92 due to the exclusion of six
unreliable determinations with coefficients of variation >15%. MMP-8 relation with
salivary HCMV IgG was not statistically significant when cases with determinations
above the assay’s limit of sensitivity were excluded from analysis (10 additional
cases excluded due to the limits of the assay). *p < 0.05, **p < 0.01, ***p < 0.001.
TABLE 4 | Correspondence between human cytomegalovirus IgG test results
using serum and salivary biospecimens from healthy adults (N = 96).
POSITIVE SERUM TEST NEGATIVE SERUM TEST Total
Positive Saliva Test 18 0 18
Negative Saliva Test 9 59 68
Equivocal Saliva Test 8 2 10
Total 35 61
Thresholds for positive, negative, and equivocal test results were defined by the
assay kit. Correctly classified cases (saliva test result = serum test result) are shown
in gray cells with bolded text.
African American participants n = 62), and the results showed no
significant effects of race in these models and minimal changes in
the associations of interest.
Results from models stratified by HCMV IgG serostatus
(seropositive n = 35; seronegative n = 61) were similar to those
reported above. As seen with the correlation analyses, in stratified
linear regression models, the serum-saliva relation for HCMV
IgG was statistically significant among seropositive participants
[unadjusted relation: b = 0.04, t(33) = 3.21, p < 0.01; adjusted
relation: b = 0.04, t(27) = 5.44, p < 0.001] and not significant or
marginal among seronegative participants [unadjusted relation:
b = 0.15, t(59) = 1.53, p = 0.13; adjusted relation: b = 0.16,
t(53) = 1.81, p = 0.08]. Also, similar to results from models with
the full analytic sample, the serum-saliva relation for HCMV
IgG was not significantly moderated by salivary total IgG nor
transferrin in the seropositive nor seronegative subgroups.
The main findings were robust to influential points and cases
with high residuals. However, it is notable that in a sensitivity
analysis that excluded one influential case, there was a marginally
significant moderating effect of salivary total IgG on the HCMV
IgG serum-saliva relation [b =−0.00, t(82) =−1.84, p = 0.07].
DISCUSSION
Human cytomegalovirus IgG levels measured in whole saliva
have the potential to be useful proxies for serum levels. The
associations between salivary and serum HCMV IgG levels were
robust. That is, the cross-specimen association was strong even
after taking into account a range of potential confounders related
to the oral environment (e.g., blood contamination and oral
inflammation) and participant characteristics. With the exception
of race, which showed the expected distribution of higher HCMV
antibody levels among African American compared to white
participants (38), none of the demographic nor physical health
characteristics examined were associated with HCMV antibody
levels in serum nor saliva in our sample of healthy adults. Across
all participants, for every one unit increase in serum HCMV IgG
level, there was approximately a 1.05 unit increase in median
salivary levels (median increase approximates increase in the
geometric mean after log transformation), and serum HCMV
IgG level explained over 60% of the variance in salivary HCMV
IgG level (η2s > 0.60). This relation was significant in the full
analytic sample, and, despite weaker associations among the
seronegative compared to the seropositive participants, there was
not a statistically significant difference in the magnitude of the
serum-saliva association across serostatus groups.
As expected, salivary HCMV IgG was associated with key
salivary markers related to oral inflammation (IL-1β, IL-6, IL-
8, and TNFα) and tissue integrity (MMP-8). This finding raises
a couple interesting possibilities. First, it is well established that
these indices reflect inflammatory processes in the local immune
and/or mucosal compartment (39). Therefore, it is possible that
salivary IgG levels reflect local immunity and viral activity in
the oral mucosa and salivary glands, a site of HCMV replication
and persistent infection (3, 40). Importantly, the strong serum-
saliva association for HCMV IgG levels and the finding that
the strength of this association remains when controlling for
these inflammatory and tissue integrity related markers strongly
suggests otherwise. Given that oral inflammation and tissue
damage represent both local immune activation as well as
increased permeability of the barriers separating the systemic
and local immune systems, our findings of robust serum-saliva
relations that hold when the effects of local inflammation are
accounted for support the potential utility of a salivary HCMV
IgG test in generally healthy individuals without significant oral
health problems.
Most of the HCMV IgG measured in saliva is thought
to be derived from serum (41), and we anticipated stronger
serum-saliva associations for HCMV IgG levels with increasing
concentrations of blood in the oral compartment. Interrogation
of these relations revealed that, while salivary HCMV IgG was
positively related to salivary transferrin, there was no evidence
that the strength of the serum-saliva association for HCMV IgG
varied by transferrin level. Our findings further suggest that
controlling for levels of blood leakage into the oral compartment
may not be necessary when assessing HCMV IgG correspondence
across serum and salivary samples. This is a tentative conclusion,
however, as participants in this study were generally healthy, and
individuals with acute and/or chronic physical health conditions
and oral health problems were excluded from participation.
Similarly, we expected that the strength of the serum-saliva
association for HCMV IgG would vary by the level of total IgG
present in the saliva sample. Specifically, we expected cross-
specimen associations would be poor without a sufficient level
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of salivary total IgG. This hypothesis was based on the notion
that assay performance would be compromised if the amount
of total IgG present in the saliva sample was very low. In this
study, the level of salivary total IgG had no significant effect on
the serum-saliva association for HCMV IgG. This finding was
the same when examined in the full sample, as well as within
serostatus subgroups. Results from sensitivity analyses, however,
suggest that additional research with larger, more diverse study
samples may be required to test these relations.
Despite a robust serum-saliva association for HCMV IgG
levels, only about half of the participants who tested positive
for HCMV IgG in serum also tested positive in saliva (51%
sensitivity). The poor performance of the salivary test in
identifying seropositive participants could be due to several
factors, most of which may relate to the suboptimal performance
of this particular assay when used with saliva. While the findings
from our linear regression models showed no evidence of
salivary total IgG levels moderating the serum-saliva relation, an
indicator of assay performance, we suspect some false negative
and equivocal test results from the salivary assay may be related to
lower levels of salivary total IgG in the sample. For saliva samples
with low total IgG concentrations, assay performance must be
very high to capture HCMV antibodies and correctly identify
a positive serostatus individual. In these cases, the percent of
HCMV antibody in circulation entering the oral cavity may be
lower relative to total IgG present in saliva. However, when
total IgG levels in saliva are high, it may be easier to identify
positive cases. Indeed, findings from our sensitivity analyses
suggest total IgG may be playing a role in assay performance,
and participants who were misclassified by the salivary test as
either negative for HCMV (n = 9) or equivocal (n = 8) had,
on average, lower levels salivary total IgG than true positive
cases (i.e., positive test results from both serum and salivary tests
(n = 18); salivary total IgG- Mmisclassified(SD) = 10.45 µg/mL
(11.26) vs. Mtrue positives(SD) = 29.87 µg/mL (23.83); z(33) = 3.17,
p < 0.01). These misclassified cases, however, also had
lower concentrations of salivary transferrin, proinflammatory
cytokines, and MMP-8 (p’s< 0.05).
With our data, we are not able to delineate key variables
underlying the salivary test sensitivity. The specificity of the
salivary test, however, was high with nearly all the participants
testing negative for HCMV IgG in serum also testing negative in
saliva (97% specificity). Furthermore, there were no false positive
salivary test results (100% positive predictive value for the salivary
test). Future research should examine whether a salivary total IgG
threshold could be used in salivary HCMV IgG screening to help
decrease the false negative rate and improve the sensitivity for
determining exposure status. With this testing criterion in place,
assay results from saliva samples that do not meet a cut-off level
for total IgG concentration would be considered unreliable, and
samples would have to be recollected.
Several limitations of our study warrant discussion. First,
this preliminary study used a commercially available diagnostic
serum/plasma HCMV IgG assay to determine both salivary
and serum HCMV antibody levels. The kit has a reported
diagnostic specificity of 99.09% and sensitivity of 99.25%, making
it an outstanding measure of exposure status when used in
serum. The qualitative results (seropositive vs. seronegative)
generated from this assay are based on antibody level
determinations that are internally consistent within a biofluid,
but estimated relative to the assay specifications, making cross-
biospecimen comparisons inappropriate. Relative differences
between antibody concentrations within a biofluid are estimated
by sample absorbance values compared to the assay controls, so
the ranking of antibody determinations, and differences among
them, are also biofluid-specific. From a research perspective,
these data allow us to examine associations between antibody
levels in serum and saliva as well as associations between
antibody levels and concentrations of other analytes. However,
more advanced methods for determining HCMV antibody levels,
particularly in saliva, are needed to support clinical investigations
and applications of the research questions examined in this
study. Adjusting the saliva sample collection and optimizing
assay procedures specifically for use with saliva may improve
the performance of future assessments of salivary HCMV IgG
levels. For example, the assay protocol calls for repeat testing
of samples with equivocal results, which, if instituted in the
current study, could have helped classify a greater proportion of
our salivary test results into a HCMV exposure group. We also
used the cut-off concentrations provided in the kit to determine
HCMV status using both serum and salivary biospecimens. Since
the kit was designed for serum testing, additional research is
needed to determine the most appropriate cut-off values for
HCMV IgG levels measured in saliva and the factors that may
influence these levels. In addition, we tested saliva samples neat
to maximize antibody concentrations and assay performance,
and future research should further examine changes in sample
collection protocols that could improve assay performance, such
as testing antibody-rich gingival crevicular fluid (GCF) or oral
mucosal transudate (OMT). These forms of oral fluids are distinct
from saliva. In contrast to the composition of saliva, both GCF
and OMT represent more of an admixture of serum constituents
[see (28) for review]. Not surprisingly, in prior studies, markers
of viral infection and inflammation correlate with serum more
strongly when measured in these admixture-type oral fluids than
saliva [e.g., (42)]. Like whole saliva, acquisition of GCF and OMT
is minimally invasive and easily repeatable. Therefore, future
studies on the measurement of HCMV IgG levels that include
GCF and OMT in comparison to saliva are well worthwhile.
In addition, several other, largely serum-based, HCMV testing
approaches are currently available, including via cell culture
and immunohistochemistry, IgM and IgA antibody detection,
and viral DNA testing methods (25). Assessments of HCMV
IgG avidity have also been shown to indicate time since
HCMV infection and distinguish between primary and previous
infection (43). While HCMV IgG testing can provide valuable
information about exposure status, it is unclear how much
information about time since exposure and viral shedding
HCMV IgG tests alone can provide, especially in the absence
of repeat testing (44–46). For saliva-based assessments, studies
employing repeated measurements and longitudinal designs are
also needed to examine the stability of salivary HCMV IgG
levels as several factors, such as flow rate, oral injuries, and
immune status, may influence IgG concentrations and affect
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the accuracy of the salivary HCMV IgG tests. Despite these
limitations in interpretability, and technical limitations related
to assay sensitivity, there are several advantages of saliva-based
HCMV testing, including increased feasibility and acceptability
in non-clinical settings and minimally invasive assessment of
exposure status, that support the development of a salivary
HCMV test for advancing research and public health. Future
research should focus on optimizing assay performance as well as
explore the utility of alternate saliva-based measures of HCMV
infection (e.g., other antibodies and indices of viral shedding).
The generalizability and interpretability of the current findings
are also constrained by the relative homogeneity of our study
sample and the small number of HCMV positive participants.
While the pattern of findings within our analytic sample was
robust to sensitivity analyses and extreme and/or influential
points, we excluded one participant from our analyses because
this participant showed an aberrant pattern of associations and
highly influenced the trends observed in the rest of the study
sample. This participant had high levels of nearly all salivary
analytes, and we believe other, unmeasured, characteristics of this
individual may be needed to understand the analyte levels and
associations observed (e.g., oral or physical health problems).
Additional research conducted in larger, more diverse samples
with higher proportions of HCMV seropositive individuals,
as well as clinical samples, is needed to fully understand the
nature of HCMV IgG levels in saliva and the utility of these
measurements for biomedical and research purposes.
It is also important to note two limitations regarding
measurements in our study. First, the use of salivary total
protein as a surrogate marker for flow rate is disputed in the
field (47–51), and future research should assess flow rate and
salivary HCMV IgG level relations more directly. Also, 10%
(n = 10) of our participants had concentrations of salivary
MMP-8 that exceeded the assay limits of sensitivity. For these
individuals, we replaced their MMP-8 concentrations with
the maximum measurable concentration for the assay and
used sensitivity analyses to examine whether this substitution
approach significantly impacted our findings. When used as a
covariate, the main findings were largely unchanged, however,
the positive relation between salivary HCMV IgG level and
MMP-8 was not significant when participants with MMP-8
concentrations exceeding the assay limits were excluded from
analysis. Studies conducted among larger, more heterogeneous
samples, with greater diversity in oral and physical health
conditions, and a greater proportion of HCMV exposed
participants are needed to confirm our findings and broaden our
understanding of the promise and potential problems related to
salivary HCMV IgG testing.
Conclusion
With additional research to improve assay performance and
optimize the type of oral fluid sampled (i.e., saliva, GCF, or
OMT), HCMV IgG testing using oral fluids has the potential to
enable minimally invasive screening for HCMV exposure on a
large-scale. This possibility could have important implications for
public health surveillance and research examining the etiology
of HCMV-related diseases. Moreover, there may be clinical
applications related to helping determine exposure status among
at-risk patients, such as women of childbearing age and the
immunocompromised. In addition to expanding testing options
for determining HCMV exposure status, salivary measurement
of HCMV IgG levels could also open up new opportunities to
study the effects of HCMV infection on health in general. HCMV
IgG levels have been associated with aging and all-cause mortality
(7, 13, 14). If confirmed, our findings of significant cross-
specimen correlations for HCMV IgG levels would support these
investigations by allowing the minimally invasive measurement
of HCMV antibody levels. While additional research using larger
and more diverse samples is needed, our findings suggest that,
with further technical development, HCMV IgG testing with
oral fluids may be an easily-measurable and interpretable proxy
for serum HCMV IgG levels. Measuring HCMV IgG levels in
oral fluid may be a feasible and reliable approach to advance
biobehavioral, clinical, and public health research and practice.
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